Nusinersen is manufactured by Biogen and is used to treat spinal muscular atrophy. ## Compulsory licenses Compulsory licenses have been issued for Nusinersen in the following instance: ### Norway issued on May 01, 2018 [[Norway]]'s provisions on compulsory licences can be in Sections 45 to 50a of the Patents Act (Act No. 9 of December 15, 1967). There are different grounds for obtaining a compulsory licence, with different requirements to be considered by the competent authority. More information can be found [here](https://e-courses.epo.org/wbts_int/CompulsoryLicensing/CL_NO.pdf). However, a compulsory license has not been executed for Nusinersen in this case because: it was rejected. ## Other products issued by the same manufacturer [[Nusinersen]] ## Other products for the same disease